José Dinis

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Steven M. Grunberg, Daniel T. T. Chua, Anish Maru et al. · Journal of Clinical Oncology · 2011 · 219 citations · Full text

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Ezra E.W. Cohen, Kevin J. Harrington, Christophe Le Tourneau et al. · Annals of Oncology · 2017 · 87 citations

Medicine, Clinical Trials, R/m Hnscc +8

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

Vassiliki Saloura, Ezra E.W. Cohen, Lisa Licitra et al. · Cancer Chemotherapy and Pharmacology · 2014 · 85 citations

Phase Ii Trial, Malignant Disease, Open-label Single-arm +9

Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution

Ramon Andrade de Mello, Sandra Gerós, Marcos Pantarotto et al. · PLoS ONE · 2014 · 51 citations · Full text